SCHEMBL4413837

SCHEMBL4413837

CCOC(=O)CNCCNS(=O)(=O)c1nnc(-c2ccc(Cl)cc2Cl)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
KDM4E B2RXH2 4/20 0.45
TSHR P16473 2/20 0.41
POLB P06746 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
GAA P10253 3/20 0.37
ALDH1A1 P00352 3/20 0.37
RAB9A P51151 2/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4418426 0.93 KMT2A (0.42) MAPTKDM4ETSHRPOLBKMT2A
SCHEMBL6458867 0.88 MAPT (0.43) MAPTKDM4ETSHRPOLBKMT2A
SCHEMBL4412181 0.88 KMT2A (0.39) MAPTKDM4EPOLBKMT2AMEN1
SCHEMBL4413761 0.86 MAPT (0.41) MAPTKDM4EPOLBKMT2AMEN1
SCHEMBL6458870 0.84 MAPT (0.42) MAPTKDM4ETSHRPOLBKMT2A
SCHEMBL4418662 0.80 LTA4H (0.43) KDM4ECDC7DBF4ALDH1A1RAB9A
SCHEMBL4411288 0.78 DDX3X (0.42) MAPTKDM4EGAAALDH1A1RAB9A
SCHEMBL3136533 0.78 CA2 (0.42) POLBKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL4417022 0.77 CA1 (0.39) MAPTTSHRKMT2AGAAALDH1A1
SCHEMBL4412465 0.76 CSNK2A2 (0.47) MAPTKMT2AMEN1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651642-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-11-04 EP disclosed
US-7211668-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2007-05-01 US disclosed
EP-1651642-A4 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2006-11-29 EP disclosed
EP-1651642-A1 PNA MONOMER AND PRECURSOR Panagene Inc. (KR) 2006-05-03 EP disclosed
US-20050026930-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-02-03 US disclosed
WO-2005009998-A1 PNA MONOMER AND PRECURSOR PANAGENE INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026930-A1 PNA monomer and precursor RNGTT, POLL, NSUN3 MAPT 4633/4885KDM4E 4872/4885TSHR 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.